Call to Schedule Free Consultation at Over 80 Centers Worldwide!

(844) GET-STEM

Stem Cells for Athletic Knee Injuries: Evidence, Regulation, and Realistic Expectations

Written by Dr. David Greene, MD, PhD, MBA on June 16, 2026

Table of Contents

Professional fighters place extraordinary, repetitive stress on their joints and connective tissue over the course of a career. Chronic knee pain and forearm or elbow overuse injuries often become the deciding factor in how long an athlete can keep competing. That reality has fueled growing interest in regenerative medicine, particularly therapies involving umbilical cord-derived stem cells, exosomes, and platelet-rich plasma (PRP), as a non-surgical option for managing pain and supporting tissue repair. This article looks at what these therapies involve, what the current evidence actually supports, and what patients researching providers such as R3 Stem Cell in Nashville should know before moving forward.

What These Therapies Involve

Regenerative treatments for joint pain typically combine three biologic components.

Umbilical cord mesenchymal stem cells (UC-MSCs) come from donated umbilical cord tissue, often containing Wharton’s jelly, a connective tissue rich in mesenchymal stem cells. Because they come from screened donor tissue rather than the patient’s own body, this is considered an allogeneic therapy, distinct from approaches using a patient’s own bone marrow or fat tissue.

Exosomes are tiny extracellular vesicles released by stem cells. They share biological functions similar to mesenchymal stem cells but tend to be more stable under varying conditions, with a comparatively lower risk of immune rejection. Patients sometimes conflate the two, and understanding how exosomes differ from stem cells clarifies why both are often used together.

Platelet-rich plasma (PRP) is created by concentrating platelets from a patient’s own blood. It has a longer clinical track record in sports medicine than cord-derived products and is often combined with them in a single treatment session.

What the Evidence Actually Shows

Knee osteoarthritis, the kind a long-time combat athlete might develop in a frequently stressed joint, involves progressive cartilage breakdown and inflammation. As cartilage loss progresses, patients experience osteophyte formation, restricted mobility, and pain that significantly affects quality of life, which is why umbilical cord mesenchymal stem cells have been increasingly studied for their potential to support cartilage-forming activity, a topic covered further in recent research on stem cell therapy for knee arthritis.

A 2025 study in the Journal of Translational Medicine offers one of the more rigorous looks at this question. Researchers extracted umbilical cord mesenchymal stem cells, verified the exosomes’ structure and surface markers, and ran both laboratory experiments on cartilage cells and a randomized, double-blind, dose-escalation human trial to test safety and effectiveness for osteoarthritis. That design represents meaningful progress, but it remains part of an evolving evidence base rather than a settled conclusion.

Other early work is underway. A separate translational study is testing umbilical cord stem cell-derived conditioned media, injected directly into the knee joint, building on findings that these products may have tissue-regenerating, anti-inflammatory, and anti-apoptotic properties. Longer-term safety data is also accumulating: one registry following patients for three years post-treatment reported no observed tumor formation, joint deformity, or immune rejection, with stable tumor markers supporting the therapy’s safety profile. Registry data carries less weight than randomized trials, so this should be read as encouraging rather than conclusive.

The honest summary: there is genuine scientific interest and some promising early data, but evidence supporting routine clinical use has not yet reached the level of long-established, FDA-approved orthopedic treatments. Outcomes can vary based on dose, delivery method, and product quality, which is part of why reviewing the risk-benefit profile of mesenchymal stem cell therapy is worthwhile before proceeding.

What Patients Need to Know About Regulation

This is the area most often misunderstood. According to the FDA’s official list of approved cellular and gene therapy products, no products using engineered or expanded mesenchymal stem cells have received FDA approval for any orthopedic application. The only stem cell products currently FDA-approved for use in the United States are blood-forming stem cells, also called hematopoietic progenitor cells, used for certain blood disorders. A fuller explanation of how these classifications work is available in this overview of FDA regulations on human cell and tissue-based products.

That doesn’t make these therapies illegal or automatically unsafe, but it does mean they sit outside the FDA’s formal approval pathway for treating arthritis or sports injuries specifically. The FDA has acknowledged that hundreds, if not thousands, of clinics have made unproven and unapproved stem cell treatments widely available for conditions ranging from common sports injuries to neurological diseases, even as the agency continues pursuing legal action to enforce its regulatory authority.

State law is shifting independently of federal approval. Effective July 1, 2025, Florida passed legislation allowing physicians to use non-FDA-approved stem cell therapies for certain orthopedic, wound care, or pain management procedures within their scope of practice, while requiring ethically sourced cells and prohibiting tissue derived from aborted fetuses or embryos. Tennessee followed in 2026, passing a law establishing the state’s first comprehensive framework for lawful stem cell and regenerative therapy, authorizing physicians to administer allogeneic stem cells sourced from screened donor tissue such as umbilical cord and placental tissue. State authorization is not the same as FDA approval, and both facts can be true at once.

How Treatment Is Typically Administered

Component

Delivery Method

Purpose

Umbilical cord stem cells

IV infusion / local injection

Support tissue repair signaling

Exosomes

IV infusion / local injection

Deliver anti-inflammatory signals

PRP

Local injection

Concentrated growth factors from the patient’s own blood

Vitamin infusion

IV infusion

General wellness support, not disease-specific

A typical visit often starts with a systemic IV infusion, followed by targeted injections into the affected joint, guided by ultrasound or direct visualization, a technique supported by musculoskeletal and orthopedic ultrasound injection training for improved placement accuracy.

Questions Worth Asking Before Treatment

What cell count or concentration is being used, and how is it verified?

Ask for the exact cell count per vial and the lab’s certificate of analysis for that specific batch, not a general marketing figure.

Is the tissue source FDA-registered, and how is donor tissue screened?

Tissue should come from an FDA-registered bank following Good Tissue Practice rules, with donor screening for infectious disease and sterility testing on the final product.

What does the clinic's own outcomes data show compared to peer-reviewed research?

Most clinics rely on patient satisfaction surveys, not controlled trials. Ask whether their numbers come from published research or just internal tracking.

What are the realistic risks, including infection or lack of response?

Risks include infection, immune reaction, and simply not responding to treatment. Ask what percentage of patients see no improvement, not just success stories.

How does this treatment fit within current state and federal regulations?

These therapies aren’t FDA-approved for orthopedic use. Some states, like Tennessee and Florida, now permit them under specific state laws, so ask which framework the clinic operates under.

The Bottom Line

Regenerative therapies using umbilical cord stem cells, exosomes, and PRP represent an active, evolving area of research with some encouraging early data for knee osteoarthritis. They remain outside the FDA’s approval pathway for orthopedic use, so patients should apply the same scrutiny to marketing claims and athlete testimonials that they would to any emerging treatment. Discussing options with both a regenerative medicine provider and an independent treating physician supports a fully informed decision.

Contact Us

iPSCs are not the same as stem cell therapies currently in use. Mesenchymal stem cell (MSC) therapies — derived from umbilical cord tissue, bone marrow, or fat — are available now and work through anti-inflammatory signaling and immune modulation rather than direct tissue replacement.

It’s also worth understanding the difference between stem cell therapy and other regenerative approaches, and how regenerative medicine differs from traditional medicine.

R3 Stem Cell, operating across 80+ centers in eight countries, focuses on these established therapies while monitoring iPSC developments as the science matures. Learn more about what regenerative medicine is and the benefits of regenerative medicine.

Stem cell therapy for diabetes is not yet a standard of care in most countries and is generally considered investigational or complementary. Patients should review FDA regulations on cell therapies for context.

The shift in thinking began with a significant clinical study from Stanford University, published in Stroke in 2016. Researchers injected mesenchymal stem cells directly into the brains of chronic stroke patients through surgically drilled openings. The results were striking — patients who were years past their strokes showed measurable improvements in motor function, with no serious adverse events linked to the stem cells.

A follow-up phase 2b trial confirmed both the safety profile and the continued functional benefit.

The key finding was not just that patients improved — it was when they improved. These were patients well outside the traditional recovery window, which proved that the brain retains the capacity to respond to regenerative signals long after injury. To understand more about how stem cell therapy works at the biological level, it helps to look at the signaling and repair mechanisms that make these results possible.

Why Dr. Hector is "Passionate" About the Word "Natural"

DNA Mutations — The reprogramming process can introduce genetic mutations — either pre-existing or induced — that raise serious safety concerns before cells can be used in patients.

Consent alone is not sufficient. Donor mothers also undergo comprehensive medical screening, which typically includes:

What Does the Bioethics Community Say?